ArticleCurrent microbiology2026
A Broad-Spectrum Antagonistic Bacillus Velezensis Strain HY17 as a Potential Biocontrol Agent Aagainst Major Maize Fungal Diseases.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Maize fungal diseases seriously threaten crop productivity and grain quality, highlighting the need for effective and sustainable biocontrol agents. In this study, an antagonistic bacterium, HY17, was isolated from maize rhizosphere soil and identified as Bacillus velezensis based on morphological characterization and phylogenomic analysis. HY17 exhibited broad-spectrum antifungal activity against several major maize fungal pathogens. Its cell-free fermentation supernatant showed clear concentration-dependent inhibition of fungal growth, indicating that extracellular metabolites play an important role in their antagonistic activity. HY17 also displayed broad growth adaptability under different culture media, temperature, and pH conditions. Whole-genome analysis revealed that HY17 contains a chromosome of 3,931,127 bp and multiple biosynthetic gene clusters associated with antimicrobial secondary metabolites. Crude lipopeptide extracts from HY17 further exhibited concentration-dependent antifungal activity. PCR assays detected representative antimicrobial biosynthetic genes, including bacA, bmyB, ituC, fenD, and srfAA, and LC-MS analysis revealed characteristic ion peaks putatively assigned to iturin-family lipopeptides and a fengycin-family component. Collectively, these results indicate that B. velezensis HY17 is a promising biocontrol candidate for maize fungal diseases, with lipopeptide-related metabolites likely contributing substantially to its broad-spectrum antifungal activity.
Indexed as
Identifiers
42873283What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.